朱惠娟, 王任直. 垂体腺瘤临床诊治进展[J]. 协和医学杂志, 2020, 11(5): 533-536. DOI: 10.3969/j.issn.1674-9081.2020.05.007
引用本文: 朱惠娟, 王任直. 垂体腺瘤临床诊治进展[J]. 协和医学杂志, 2020, 11(5): 533-536. DOI: 10.3969/j.issn.1674-9081.2020.05.007
Hui-juan ZHU, Ren-zhi WANG. Clinical Diagnosis and Treatment of Pituitary Adenomas[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 533-536. DOI: 10.3969/j.issn.1674-9081.2020.05.007
Citation: Hui-juan ZHU, Ren-zhi WANG. Clinical Diagnosis and Treatment of Pituitary Adenomas[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 533-536. DOI: 10.3969/j.issn.1674-9081.2020.05.007

垂体腺瘤临床诊治进展

Clinical Diagnosis and Treatment of Pituitary Adenomas

  • 摘要: 垂体腺瘤是较常见的神经内分泌肿瘤,多为良性,但其高分泌激素或大腺瘤干扰腺垂体及周围组织器官的正常功能,严重影响患者的健康和预后。多学科参与的规范诊疗是垂体腺瘤临床应对的重要原则。2017年世界卫生组织第4次修订了垂体腺瘤的病理诊断分类,高危垂体腺瘤和难治性垂体腺瘤依然是临床诊治的难点,存在诸多挑战,而垂体腺瘤的发生机制和潜在治疗靶点亦有待进一步揭示。本文系统总结了垂体腺瘤的发病机制和临床诊治进展。

     

    Abstract: Pituitary adenomas (PAs) are a kind of neuroendocrine neoplasm(NEN)and mostly benign. However, the hyper function of adenohypophysis and the compression to surrounding tissues and organs are often seriously presented in macroadenomas. The standardized diagnosis and treatment of PAs by multidisciplinary team is important. In 2017, the World Health Organization (WHO) revised the pathological diagnosis classification of PAs for the fourth time. High risk PAs and refractory PAs are still challenge in clinical diagnosis and treatment. The mechanism and potential therapeutic target of PAs need to be further revealed. The pathogenesis and clinical diagnosis and treatment of pituitary adenomas were reviewed.

     

/

返回文章
返回